The Snippet : Merck Focuses its Research on Hard to Treat Cancers

Posted on


Merck is a leading science and technology company, and has many projects that are involved in research to find treatments for diseases that are hard to treat. Keeping in view with this agenda, Merck has announced that the new research that has been conducted from their marketed and pipeline compounds will be presented at this year’s European Society for Medical Oncology annual meeting in Denmark. The presentations are to be focussed on hard-to-treat cancers, and will include results for Erbitux® (cetuximab) in metastatic colorectal cancer (mCRC) and squamous cell carcinoma of the head and neck (SCCHN); preliminary study results in bladder cancer and renal cell carcinoma (RCC) for avelumab, which is being developed in collaboration with Pfizer; and updates on the Phase II program for tepotinib* in non-small cell lung cancer (NSCLC).

To know more, click on the link below:

http://www.bioportfolio.com/news/article/2854515/Merck-to-Present-New-Research-Focused-on-Hard-to-Treat-Cancers-at.html

 

Advertisements